This study is currently not recruiting participants.

A Phase 1a/1b Open Label Dose-escalation Safety and Tolerability Study of INCB052793 in Subjects With Advanced Malignancies

Investigating Safe and Tolerable Doses of an Investigational Medication for Advanced Cancer

Not Recruiting
100 years or below
All
Phase N/A

Brief description of study.

The purpose of this study is to determine the dose of INCB052793 that is safe and tolerable in subjects with advanced cancer and to select the doses that will be studied further, and to assess the safety of INCB052793 in combination with gemcitabine and nab-paclitaxel in subjects with advanced solid tumors.

Detailed description of study

The purpose of this study is to determine the dose of INCB052793 that is safe and tolerable in subjects with advanced cancer and to select the doses that will be studied further, and to assess the safety of INCB052793 in combination with gemcitabine and nab-paclitaxel in subjects with advanced solid tumors.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: Advanced Malignancy
  • Age: 100 years or below
  • Gender: All

The purpose of this study is to determine the dose of an investigational medication that is safe and tolerable in people with advanced cancer. This study also aims to assess the safety of the investigational medication when used with other treatments for advanced solid tumors. Advanced cancer refers to cancer that has spread from where it started to other parts of the body.

Participants in this study will receive doses of the investigational medication. Some participants will also receive the investigational medication in combination with other treatments. The study will monitor the safety and effects of these treatments.

  • Who can participate: Participants must be adults diagnosed with advanced cancer, which means the cancer has spread to other parts of the body. Additional eligibility criteria may include specific health conditions or treatment history.
  • Study details: Participants will receive an investigational medication, and some may also receive it in combination with other treatments. The study will focus on monitoring the safety and effects of these treatments.
Updated on 19 Feb 2024. Study ID: 1410591339

Interested in the study?

Select a study center that’s convenient for you, and get in touch with the study team.

Connect with the study team